Commonwealth of Pennsylvania Public School Empls Retrmt SYS Makes New Investment in Drugs Made In America Acquisition II Corp. $DMII

Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new position in shares of Drugs Made In America Acquisition II Corp. (NASDAQ:DMII) in the fourth quarter, Holdings Channel reports. The fund acquired 400,000 shares of the company’s stock, valued at approximately $3,960,000.

A number of other hedge funds also recently added to or reduced their stakes in DMII. Wolverine Asset Management LLC acquired a new stake in Drugs Made In America Acquisition II during the 4th quarter worth approximately $10,521,000. HighTower Advisors LLC acquired a new stake in Drugs Made In America Acquisition II during the 4th quarter worth approximately $7,817,000. Wealthspring Capital LLC acquired a new stake in Drugs Made In America Acquisition II during the 4th quarter worth approximately $4,049,000. Deltec Asset Management LLC acquired a new stake in Drugs Made In America Acquisition II during the 4th quarter worth approximately $495,000. Finally, ABC Arbitrage SA acquired a new stake in Drugs Made In America Acquisition II during the 4th quarter worth approximately $396,000.

Drugs Made In America Acquisition II Stock Up 0.0%

DMII opened at $10.08 on Thursday. The company has a 50 day simple moving average of $10.02. Drugs Made In America Acquisition II Corp. has a 12 month low of $9.86 and a 12 month high of $10.07.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on DMII. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Drugs Made In America Acquisition II in a research report on Friday, May 29th. Wall Street Zen raised Drugs Made In America Acquisition II from a “sell” rating to a “hold” rating in a report on Sunday, May 10th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.

About Drugs Made In America Acquisition II

Drugs Made In America Acquisition II (NASDAQ:DMII) is a special purpose acquisition company (SPAC) formed to raise capital through a public listing for the purpose of effecting a business combination. As a blank‑check vehicle, the company itself does not operate a traditional commercial business; instead, it seeks to identify, negotiate and complete an acquisition, merger, share exchange, asset purchase or similar business transaction with one or more target companies.

The stated investment focus reflected in the company’s name indicates an emphasis on the pharmaceutical and life sciences sector, with a particular interest in domestic drug manufacturing, supply‑chain resiliency and related healthcare operations in the United States.